Applications for our Master’s programmes for entry September 2018 are now open!

Applications for our Master’s programmes for entry September 2018 are now open!

When you apply for our Master’s programmes, it is important to consider financing of your tuition fees and living expenses for the duration of your programme. There are different possibilities of obtaining financial support.

We highlight some of the most pertinent sources here, but recommend that you also search King’s postgraduate funding database.

Global Health & Social Medicine scholarship

Global Health & Social Medicine will be offering one Master’s Award of £9,000 for 2018/19 entry for a full-time student onto one of our programmes. All students, including those from the UK, EU and overseas, are eligible.

There is no separate application procedure for the scholarship. If you have submitted a complete application by midnight (UK time) on 31 March in the given year, you will automatically be considered for the scholarship. A fully completed application includes a complete online application form, and also all supporting documents including personal statements, transcripts, references and IELTS certificates where appropriate. All materials must have been submitted via the Postgraduate Admissions Portal by the due time and date.

Each of our programmes will identify its top two candidates, based on previous academic performance, relevant experience (where appropriate) and the personal statement indicating reasons for applying to a particular programme.

A departmental panel will decide the top candidate and award the scholarship. The successful candidates will be notified by 15 May at the latest in the given year.

Scholarship Recipients

  • Johanna Eichinger, MSc Bioethics & Society, 2017/18

Bursary Recipients

  • Gareth Black, MSc Bioethics & Society – part time, 2017/18
  • Heilien Diedericks, MSc Bioethics & Society, 2017/18
  • Ilma Molnar, MSc Global Health & Social Justice, 2017/18
  • Louisa Howard, MA Bioethics & Society, 2016/17
  • Sara Cheloni, MSc Gerontology, 2016/17
Posted in Ageing, Bioethics, Gerontology, Global Health, Global Health & Social Justice, MA in Bioethics & Soicety, Medicine Health and Public Policy | Tagged , | Leave a comment

Sign-up is now open for this term 1st GHSM Medical London Excursion on Wednesday 18th October, to the Migration Museum Project!

Date:   Wednesday 18th October 

Time:   14:15-16:30 

We’ll be heading to the Migration Museum Project, the UK’s first dedicated museum of migration.


Meeting point:

Migration Museum Project lobby

 The address is:

Migration Museum Project lobby

The Workshop

26 Lambeth High Street, London SE1 7AG

Nearest tubes: Vauxhall and Lambeth North

Places are free of charge and can be booked via Eventbrite (please book only once and be sure to cancel your place if you can no longer make it):

The Migration Museum Project tells stories of movement to and from Britain in fresh and engaging ways. The museum is currently at The Workshop, an exciting temporary arts and community space near Albert Embankment. We will get a tour of the museum’s current exhibition ‘No Turning Back: Seven Migration Moments that Changed Britain.’ This exhibition explores seven turning points related to migration in Britain.The museum says of these moments that ‘…some brought people together, others moved people apart; all had a profound effect on individuals who lived through them – and on the country as a whole. Each moment is explored thematically through a combination of art, photography and personal stories.’

After the trip, you can reflect on your experience either as an individual or in a group writing exercise, eligible for publication on the departmental blog:

 We look forward to seeing many of you on the 18th October!

Best wishes,

Priya Umachandran & Nancy Tamimi

 If you have any questions  feel free to get in touch with Priya:
Posted in London Medical Excursion | Tagged , | Leave a comment

New study led by Dr Courtney Davis published in the BMJ today shows that most new cancer drugs entering the European market are failing to deliver any clinically meaningful benefit

Almost two thirds (57%) of cancer drugs authorised by the European Medicines Agency (EMA) between 2003 and 2009 came onto the market without any clear evidence they improved the quality or quantity of patients’ lives, according to research from King’s College London and the London School of Economics and Political Science (LSE),  published in the BMJ today.

The research team, led byDr Courtney Davis (GHSM, King’s College London),  Dr Ajay Aggarwal (from the Institute of Cancer Policy at King’s) and Dr Huseyin Naci (LSE), and  funded by Health Action International, found most cancer drugs are approved by the EMA using only surrogate measures which, although indicators, are not strong predictors of survival – whether living longer or feeling better.


Dr Courtney Davis

Dr Courtney Davis, a medical and political sociologist in the Department of Global Health and Social Medicine at King’s College London who led the team said: ‘We evaluated the evidence base for all new drugs entering the market over a 5 year period and found that the majority came onto the market without clear evidence that they improved patients’ survival or quality of life. A large number of people are undergoing treatment for cancer and little new information is available to guide patients and their treating clinicians regarding drug effectiveness. When expensive drugs that lack robust evidence of clinical benefit are approved and reimbursed within publicly funded healthcare systems, individual patients may be harmed and public funds wasted. ’

This low level for authorisation means a significant number of cancer drugs, available on the European market and often promoted as ‘breakthrough therapies’, have no actual demonstrable benefit over existing treatment options or placebo. This leads to false hope and exposure to unnecessary drug toxicity for some patients as well as being a significant waste of important resources and funding.

The team also found that even after a median follow-up of five years, almost half of the drugs (49%) still showed no quality or quantity of life benefit and of those that did, these benefits were judged to be clinically insignificant around 50% of the time.

As a result of these findings, the researchers are calling on the EMA to increase its evidence bar for the market authorisation of new drugs.

Notes to Editors:

For more information or interview requests with Dr Courtney Davis please contact Claire Gilby, PR Manager (Arts & Sciences), on 020 7848 3092 or

There are a number of study limitations to this research including incomplete and variable reporting of results from the EMA and the scientific literature leading to possible overestimation of the proportion of drugs that offer survival or quality of life benefits. The appropriateness of clinical trial design was not considered and the team did not take account of negative studies for the same drug-indication, so the findings do not reflect the totality of the evidence base for a specific authorised indications.

Dr Courtney Davis is also the Director of the MSc in Medicine, Health and Public Policy at King’s College London. Applications for the programme are open for entry September 2018. For more information about the MSc see here:

Posted in Medicine Health and Public Policy | Tagged , , | Leave a comment

Applications for Policy Idol 2018 now open!

Applications for Policy Idol 2018 now open, offering training, cash prizes and the chance to test your ideas and skills on a panel of experts

 Applications are now open for Policy Idol 2018, the annual competition open to all current students and staff at King’s, in which participants pitch their policy ideas to an expert panel of leading figures from the worlds of politics, academia and industry. Either individually or as part of a team, on the day contestants will have just three minutes to present their idea to the judges, who will assess the pitch on the quality of delivery and the evidence and analysis underpinning it.


Emma Wynne Bannister and Sarah Williams, Global Health and Social Justice Master’s students and finalists at Policy Idol 2016/17 competition

Organised by the Policy Institute at King’s, the competition sees the best ideas selected in a series of heats, with standout pitches from each heat put through to the grand final. All finalists receive bespoke training in policy analysis and communications, as well as an opportunity to improve their pitch.

 The final takes place in front of a live audience, with both the judges and the audience voting for their favourite idea at the end of the evening. This year’s final was hosted by the BBC’s Home Editor, Mark Easton, and the judging was carried out by a panel that included Professor Jennifer Rubin, Director of The Policy Institute at King’s; Dr Dan Poulter, Conservative MP for Central Suffolk and North Ipswich and Visiting Professor at The Policy Institute; Polly Toynbee, columnist at The Guardian; and Professor Frans Berkhout, Executive Dean of the Faculty of Social Science and Public Policy at King’s.

 The finalists’ pitches covered a diverse range of topics, including the increasing problem of smartphone addiction, how to improve working conditions for those working in the shadow trash market in Uruguay and how to engage young people to revitalise democracy. The overall winner, Louis Phelps, advocated the reduction of meat consumption to foster innovation.

We are very proud to add that two of GHSM Master’s students, Sarah Williams and Emma Wynne Bannister, were among the finalists in the 2016/17 Policy Idol Competition.

 As with this year’s competition, Policy Idol 2018 will have four cash prizes on offer, with the overall winner taking home £1,000.

Register for Policy Idol 2018

Follow us @policyatkings

Posted in Public Policy | Tagged , , | Leave a comment

New John Hopkins University Press book by Ilana Löwy, visiting Professor at GHSM: “Imperfect Pregnancies”

Posted in Bioeconomy, History of Medicine | Tagged , , , | Leave a comment